Novel GABA(A) α5 Discovery Program

Our novel GABAA α5 discovery program is evaluating MCI due to AD, autism and schizophrenia.

AgeneBio has a novel GABAA α5 small molecule program in late discovery stage being investigated for the treatment of several diseases of the central nervous system including MCI due to AD, autism and schizophrenia.

Our GABAA α5 Positive Allosteric Modulator (PAM) program builds on the science developed for the AGB101 program. With a high density of GABAA α5 receptors in the hippocampus, compounds that act as GABAA α5 PAMs are believed to have the potential to attenuate hippocampal overactivity. Proof of biology studies demonstrate that GABAA α5 PAMs from multiple structural classes occupy GABAA α5 receptors in the hippocampus and improve memory impairment in aged animals. The safety and efficacy of GABAA α5 PAMs have not been established.

Learn more in our publications.

The technology and patents behind AgeneBio’s early-stage program were discovered and initially developed by researchers at Johns Hopkins University, including the company’s founder and chief scientific officer, Michela Gallagher, PhD.

MCI due to AD and Alzheimer’s dementia patient resources

Autism patient resources

Schizophrenia patient resources